| P2093 | author name string | Karl S Peggs | |
| | Rob S Sellar | |
| P2860 | cites work | Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation | Q46594776 |
| | Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation | Q46639393 |
| | Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study | Q46656697 |
| | The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. | Q46834246 |
| | Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation | Q46849976 |
| | A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. | Q53327420 |
| | Severe herpesvirus infections in an adolescent without natural killer cells | Q55984308 |
| | A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target | Q56772570 |
| | Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies | Q24629979 |
| | A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells | Q28210870 |
| | Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective | Q28388806 |
| | Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors | Q31038987 |
| | Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes | Q31835044 |
| | Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation | Q33340924 |
| | Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro | Q33804593 |
| | Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. | Q33864322 |
| | Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies | Q33972690 |
| | Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. | Q34109321 |
| | Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication | Q34111115 |
| | Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes | Q34279175 |
| | Acyclovir: discovery, mechanism of action, and selectivity | Q34345105 |
| | Herpes simplex viruses | Q34462353 |
| | Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir | Q34507794 |
| | Herpes simplex virus resistance to antiviral drugs | Q34531396 |
| | Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy | Q34579981 |
| | Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature | Q34586519 |
| | Resistance testing of clinical varicella-zoster virus strains | Q34628959 |
| | Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models | Q43085636 |
| | Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance | Q43166686 |
| | Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation | Q43406230 |
| | Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation | Q43904839 |
| | Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease | Q43943693 |
| | Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants | Q43945207 |
| | Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. | Q43971464 |
| | Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients | Q44254747 |
| | Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity | Q44661886 |
| | Artesunate combinations for treatment of malaria: meta-analysis | Q44728450 |
| | Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation | Q44799887 |
| | Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. | Q44814759 |
| | Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection | Q45111047 |
| | Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity | Q45263287 |
| | BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses | Q45362434 |
| | Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics | Q45367682 |
| | Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients | Q45374647 |
| | Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation | Q45415157 |
| | Development of herpes simplex virus disease in patients who are receiving cidofovir | Q45428857 |
| | The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation | Q45487806 |
| | Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation | Q45740042 |
| | Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients | Q45741679 |
| | Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance | Q45742120 |
| | Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed | Q45748586 |
| | Foscarnet therapy for acyclovir-resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients | Q45769103 |
| | Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir | Q45777522 |
| | Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir | Q45800896 |
| | Acyclovir prophylaxis of herpes-simplex-virus infections | Q45802010 |
| | Infection with varicella-zoster virus after marrow transplantation | Q45828617 |
| | Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals | Q45862722 |
| | Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. | Q45916399 |
| | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group | Q46117817 |
| | Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study | Q46293092 |
| | New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease | Q34647592 |
| | Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections | Q34739517 |
| | Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. | Q35014240 |
| | Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy | Q35175290 |
| | CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections | Q35270714 |
| | Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates | Q35635817 |
| | Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. | Q35661025 |
| | Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study | Q35849423 |
| | Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial | Q35991860 |
| | Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers | Q36403280 |
| | Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation--a systematic review and evidence-based guidance for clinical management | Q37186798 |
| | The antiviral activities of artemisinin and artesunate. | Q37242654 |
| | Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes | Q37334642 |
| | Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. | Q37478310 |
| | Adoptive T cell immunotherapy for cytomegalovirus | Q37489881 |
| | Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus | Q37684876 |
| | Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients | Q37777434 |
| | Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. | Q37880277 |
| | Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections | Q37880547 |
| | Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001 | Q38441882 |
| | Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. | Q38482641 |
| | The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase | Q38631773 |
| | Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients | Q39479368 |
| | Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action | Q39652504 |
| | The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress | Q39699217 |
| | Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects | Q39743346 |
| | In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. | Q39756225 |
| | Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial | Q39770863 |
| | Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. | Q39775112 |
| | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases | Q40379324 |
| | Compilation, alignment, and phylogenetic relationships of DNA polymerases | Q40405362 |
| | A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients | Q40489721 |
| | Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. | Q40613236 |
| | Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. | Q40621588 |
| | Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study | Q40635257 |
| | Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy | Q40732151 |
| | Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses | Q40745363 |
| | Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene | Q40899970 |
| | Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients | Q41017843 |
| | Activity of penciclovir in antiviral assays against herpes simplex virus | Q41232429 |
| | In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes | Q41771574 |
| | Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells | Q42184945 |
| | 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells | Q42375929 |
| | Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes | Q42947488 |
| | Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir | Q43053807 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 559-572 | |
| P577 | publication date | 2011-12-22 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Management of multidrug-resistant viruses in the immunocompromised host | |
| P478 | volume | 156 | |